Pharmaceutical

Ibutamoren mesylate by Lumos Pharma for Growth Hormone Deficiency: Likelihood of Approval

Ibutamoren mesylate is under clinical development by Lumos Pharma and currently in Phase II for Growth Hormone Deficiency.

May 5, 2024 - 00:00
Ibutamoren mesylate is under clinical development by Lumos Pharma and currently in Phase II for Growth Hormone Deficiency.
Read the original article

Tags:

Previous Article

ImmunityBio partners with Serum Institute for BCG vaccines

Next Article

GIST-MIT CSAIL researchers develop a biomechanical dataset for badminton perform...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: U.S. Anesthesia Partners, Welsh Carson face class action over monopoly allegations

STAT+: U.S. Anesthesia Partners, Welsh Carson face clas...

Nov 23, 2023

Bird flu researchers turn to Finland’s mink farms, tracking a virus with pandemic potential

Bird flu researchers turn to Finland’s mink farms, trac...

Aug 11, 2023

Tapotoclax by Amgen for Chronic Myelomonocytic Leukemia...

Feb 8, 2024